Understand the Clinical and Strategic Challenges to the Commercialization of Anti-Angiogenic and Vascular Targeting Drugs.
With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor site, the use of targeted therapies, such as anti-angiogenesis chemotherapy agents.
Scope of this report:
- In-depth competitive landscape assessment of the anti-angiogenesis market in oncology
- Thorough review of utilized targets in anti-angiogenic and vascular target drug development
- Thorough review of approved drugs
- Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls
- Research and analysis highlights
Companies with the ten highest numbers of clinical trials make up more than 40% of all research and development done in anti-angiogenesis and vascular targeting in oncology, but they just constitute 10% of the competitors in the field.
More than 100 anti-angiogenic drugs have been described with one or more targets. These 75 drug targets are a mixture of weaker and stronger targets in angiogenesis.
The prostate cancer market is reaching maturity, and major players' sales have been eroded by the launch of various LHRH agonist depot formulations, we identify that angiogenesis inhibitors will be the most promising for future treatment of prostate cancer.
Key reasons to read this report:
- Understand the clinical and strategic challenges to the commercialization of anti-angiogenic and vascular targeting drugs
- Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications.
- Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development
- Some of the almost 100 drugs included in this analysis
2-methoxyestradiol, AMG-706, ATN-161, AZD-2171, bevacizumab, combretastatin A-4 prodrug, enzastaurin hydrochloride, everolimus, neovastat, PTK/ZK, sorafenib tosylate, squalamine, thalidomide, vitaxin, XL-999, ZD-6474, volociximab etc.
Key Chapters Covered:
- Executive Summary
- Cancer Highlights
- Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology
- Approved Anti-Angiogenic Cancer Drugs: Performance
- Target Analysis in Anti-Angiogenesis and Vascular Targeting
- Anti-angiogenesis and Vascular Targeting Drugs in Development: By Major Indications
- Drug Index
- Company Index
For more information visit http://www.researchandmarkets.com/reports/c43855
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 20, 2006|
|Previous Article:||Putting the Energy Back into Sales Management.|
|Next Article:||Spectra Logic Named One of Colorado's Fastest Growing Technology Companies in Deloitte's Colorado Technology Fast 50 Program.|